Our Pipeline

We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.
* As of October 31, 2025

Pipeline Chart

Pipeline/Category
Phase
Country/Region
  • Breast
    Breast
  • Lung
    Lung
  • Colorectal
    Colorectal
  • Ovarian
    Ovarian
  • Hematologic
    Hematologic
  • Gastric
    Gastric
  • Solid tumor
    Solid tumor
  • HCC_Hepatocellular Carcinoma
    HCC_Hepatocellular Carcinoma
  • HNSCC_Head and Neck Squamous Cell Carcinoma
    HNSCC_Head and Neck Squamous Cell Carcinoma
  • Melanoma
    Melanoma
  • Pancreatic
    Pancreatic
  • Prostate
    Prostate
  • RCC_Renal Cell Carcinoma
    RCC_Renal Cell Carcinoma
  • Urothelial-Bladder
    Urothelial-Bladder
  • Other solid tumors
    Other solid tumors

Notes

Orphan drug designation (designated in at least one country/region among JP, US)：Orphan drug designation (designated in at least one country/region among JP, US)
Breakthrough Therapy Designation (US)：Breakthrough Therapy Designation (US)
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of Phase2 trials：Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of Phase2 trials
Fast Track Designation (US)：Fast Track Designation (US)
Rare Pediatric Disease Designation (US)：Rare Pediatric Disease Designation (US)
*1 Adjuvant therapy for patients with residual invasive disease following neoadjuvant therapy
*2 Supported by data from TROPION-Lung01, TROPION-PanTumor01
AGA: actionable genomic alterations, BTC: biliary tract cancer, BC: breast cancer, CPS: combined positive score, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, HCC: hepatocellular carcinoma, HR: hormone receptor, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TBA: to be announced, TC: tumor cells, TKI: tyrosine kinase inhibitor, TNBC: triple negative breast cancer, TPS: tumor proportion score
AGA: actionable genomic alterations, AML: acute myeloid leukemia, BC: breast cancer, BCL: B cell lymphoma, ES-SCLC: extensive-stage small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TPS: tumor proportion score